Compare ZDAI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDAI | JSPR |
|---|---|---|
| Founded | 2022 | 2018 |
| Country | Hong Kong | United States |
| Employees | 33 | 22 |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 14.9M |
| IPO Year | N/A | N/A |
| Metric | ZDAI | JSPR |
|---|---|---|
| Price | $1.90 | $0.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 339.4K | ★ 732.4K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.32 |
| 52 Week High | $11.48 | $3.38 |
| Indicator | ZDAI | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.21 | 55.26 |
| Support Level | $1.71 | $0.62 |
| Resistance Level | $2.04 | $1.06 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 33.33 | 68.69 |
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.